EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Olanzapine, but not haloperidol, exerts pronounced acute metabolic effects in the methylazoxymethanol rat model

Katerina Horska iD, Silje Skrede, Jan Kucera iD, Gabriela Kuzminova, Pavel Suchy iD, Vincenzo Micale iD, Jana Ruda-Kucerova iD

CNS Neuroscience & Therapeutics · 2024

DOI: 10.1111/cns.14565 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Katerina Horska und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Masaryk University, Brno, Czech Republic. Hauptthemen laut MEDLINE: Haloperidol, Antipsychotic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MEYS and the OP RDE, Specific University Research Grant provided by Ministry of Education, Youth and Sports of the Czech Republic, SoMoPro II Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Widely used second‐generation antipsychotics are associated with adverse metabolic effects, contributing to increased cardiovascular mortality. To develop strategies to prevent or treat adverse metabolic effects, preclinical models have a clear role in uncovering underlying molecular mechanisms. However, with few exceptions, preclinical studies have been performed in healthy animals, neglecting the contribution of dysmetabolic features inherent to psychotic disorders.

Methods

In this study, methylazoxymethanol acetate (MAM) was prenatally administered to pregnant Sprague–Dawley rats at gestational day 17 to induce a well‐validated neurodevelopmental model of schizophrenia mimicking its assumed pathogenesis with persistent phenotype. Against this background, the dysmetabolic effects of acute treatment with olanzapine and haloperidol were examined in female rats.

Results

Prenatally MAM‐exposed animals exhibited several metabolic features, including lipid disturbances. Half of the MAM rats exposed to olanzapine had pronounced serum lipid profile alteration compared to non‐MAM controls, interpreted as a reflection of a delicate MAM‐induced metabolic balance disrupted by olanzapine. In accordance with the drugs' clinical metabolic profiles, olanzapine‐associated dysmetabolic effects were more pronounced than haloperidol‐associated dysmetabolic effects in non‐MAM rats and rats exposed to MAM.

Conclusion

Our results demonstrate metabolic vulnerability in female prenatally MAM‐exposed rats, indicating that findings from healthy animals likely provide an underestimated impression of metabolic dysfunction associated with antipsychotics. In the context of metabolic disturbances, neurodevelopmental models possess a relevant background, and the search for adequate animal models should receive more attention within the field of experimental psychopharmacology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HaloperidolAntipsychotic AgentsPregnancyRatsFemaleAnimalsMethylazoxymethanol AcetateOlanzapineRats, Sprague-DawleyLipidsDisease Models, Animal

Stichwörter der Autor:innen

adipokineantipsychoticlipid profilemethylazoxymethanolschizophrenia

Substanzen

HaloperidolmethylazoxymethanolMethylazoxymethanol AcetateOlanzapineAntipsychotic AgentsLipids

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Masaryk University, Brno, Czech Republic.
  • Department of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, Norway.
  • Section of Clinical Pharmacology, Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway.
  • RECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic.
  • Department of Physical Activities and Health, Faculty of Sports Studies, Masaryk University, Brno, Czech Republic.
  • Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy.

ORCID-Profile: Katerina Horska, Jan Kucera, Pavel Suchy, Vincenzo Micale, Jana Ruda-Kucerova

Förderung

  • MEYS and the OP RDE
  • Specific University Research Grant provided by Ministry of Education, Youth and Sports of the Czech Republic
  • SoMoPro II Programme
  • European Union's Horizon 2020 research and innovation program
  • EEA Grants/Norway Grants
  • Norway Grants

Zitieren

APA

Horska, K., Skrede, S., Kucera, J., Kuzminova, G., Suchy, P., Micale, V., & Ruda-Kucerova, J. (2024). Olanzapine, but not haloperidol, exerts pronounced acute metabolic effects in the methylazoxymethanol rat model. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14565

Vancouver

Horska K, Skrede S, Kucera J, Kuzminova G, Suchy P, Micale V, et al. Olanzapine, but not haloperidol, exerts pronounced acute metabolic effects in the methylazoxymethanol rat model. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.14565

BibTeX
@article{Horska2024,
  author = {Horska, Katerina and Skrede, Silje and Kucera, Jan and Kuzminova, Gabriela and Suchy, Pavel and Micale, Vincenzo and Ruda-Kucerova, Jana},
  title = {Olanzapine, but not haloperidol, exerts pronounced acute metabolic effects in the methylazoxymethanol rat model},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2024},
  doi = {10.1111/cns.14565}
}
Kostenlos starten →